Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14054MR)

This product GTTS-WQ14054MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14054MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11674MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ6378MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ6256MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ3532MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ10040MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ8576MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ9424MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ7525MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW